Introduction: Blood transfusions remain a substantial source of HIV in SSA particularly among children and pregnant women. Aims and
Introduction
The World Health Organization has estimated that there were 40 million people were infected with human immunodeficiency virus (HIV) globally at the end of 2001, and the majority of them were in developing countries [1] . The countries affected the most are The HIV antibody test offers the advantages of simplicity and cost effectiveness for verifying infection, but it is less than perfect because of the possibility of transfusing antibody negative unit from a donor in the window phase of HIV infection. Newer technologies exist that can contribute to an accurate diagnosis, assist in monitoring the response to therapy, and can be used to effectively predict disease outcome. Viral isolation through viral culture, nucleic acid tests to detect viral RNA, and tests to detect p24 antigen can be used to demonstrate virus or viral components in blood, thereby verifying infection and potentially reducing the risk of transfusion of blood in the window phase of HIV infection. The p24 antigen assay measures the viral capsid (core) p24 protein in blood that is detectable earlier than HIV antibody during acute infection. It occurs early after infection due to the initial burst of virus replication and is associated with high levels of viremia during which the individual is highly infectious but may be antibody negative [2] .
There is high rates of HIV in SSA countries and this continue to present a substantial challenge for blood services in recruiting and retaining safe blood donors. In sub-Saharan Africa, transfusiontransmitted human immunodeficiency virus (HIV) infection persists, particularly among women with pregnancy and haemorrhagerelated anaemia and children with malaria -related anaemia who are the major recipient of blood transfusions [3] . [5] . Blood transfusion services in Nigeria screen donated blood for markers of HIV infection using antibody based rapid test. The HIV antibody test offers the advantages of simplicity and cost effectiveness for verifying infection, but it is less than perfect because of the possibility of transfusing antibody negative donor unit in the window phase of HIV infection. There is paucity of data on the prevalence of p24 antigen among HIV antibody negative donors in Nigeria. HIV testing in the country is sub-optimally based on the detection of antibody to HIV virus. The risk of transfusing donor unit in the window phase of infection is unknown. Therefore, the aim of this case study was to investigate the prevalence of p24 antigen among HIV antibody negative blood donors in Sokoto, North Western, Nigeria. Evidence-based data generated will help in the formulation of policy to improve the safety of blood and blood product as well as optimize the quality of blood transfusion service delivery in Nigeria.
Methods

Study participants
This present retrospective study included a total of 15,061 blood donors who were screened at the blood transfusion unit of the [7] . P24 antigen testing was carried out using the Diapro Diagnostic immunoassay kit for P24 antigen (King Hawk Pharmaceuticals Beijing China). All initially positive samples were confirmed using the Bioprobes Sri P24 immunoassay kit (Bioprobes, Milano, Italy).
Study area
This present research work was carried out at the Haematology and 
Statistics
Statistical analyses were conducted using SPSS (version 11)
software. Comparisons between populations were made using the Student´s t-test for parametric data and the Mann-Whitney test for non-parametric data. An alpha value of <0.05 denoted a statistically significant difference. Correlation was compared using a version of linear regression analysis.
Results
A total of 15,061 blood donors were screened for HIV from January 2010 to July 2013 ( countries, but require sophisticated technology and dedicated, welltrained personnel [31] [32] [33] . NAT costs 3 to 10 times more than ELISA. There is need for low-resource countries to carefully weigh the advantages and costs of using NAT. However a previous study to estimate the number of window period infections entering the Kenyan blood supply investigated over 12,000 antibody and p24
negative specimens from six national collection centres for HIV using NAT. NAT retesting found no additional HIV infections, indicating that HIV antibody and p24 antigen screening can significantly reduce HIV in the nation´s blood supply, even in a setting with a generalized HIV epidemic [16] .
We compared the prevalence of p24 positivity based on the gender of the blood donors. P24 positivity was significantly higher among male blood donors compared to females. Our finding is at variance with previous reports in Nigeria which found the prevalence of HIV higher among females compared to males [34, 35] . The small population of females among the donor population studied may also have influenced this finding.
We compared the prevalence of p24 positivity based on the ABO 
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